15.10
price up icon4.93%   0.71
 
loading
Zymeworks Inc. stock is traded at $15.10, with a volume of 480.04K. It is up +4.93% in the last 24 hours and up +5.45% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$14.39
Open:
$14.53
24h Volume:
480.04K
Relative Volume:
1.07
Market Cap:
$1.14B
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-10.00
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
+5.15%
1M Performance:
+5.45%
6M Performance:
+4.93%
1Y Performance:
+35.30%
1-Day Range:
Value
$14.53
$15.38
1-Week Range:
Value
$13.48
$15.38
52-Week Range:
Value
$9.03
$17.70

Zymeworks Inc. Stock (ZYME) Company Profile

Name
Name
Zymeworks Inc.
Name
Phone
604-678-1388
Name
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Name
Employee
170
Name
Twitter
@ZymeworksInc
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ZYME's Discussions on Twitter

Compare ZYME with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ZYME
Zymeworks Inc.
15.10 1.06B 62.71M -112.51M -96.01M -1.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date Action Analyst Rating Change
May-20-25 Initiated TD Cowen Buy
Dec-16-24 Upgrade JP Morgan Neutral → Overweight
Nov-07-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-01-24 Downgrade Wells Fargo Overweight → Equal Weight
Mar-21-23 Resumed Wells Fargo Overweight
Jan-04-23 Reiterated H.C. Wainwright Neutral
Dec-20-22 Upgrade Jefferies Hold → Buy
Nov-01-22 Downgrade H.C. Wainwright Buy → Neutral
Oct-21-22 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-04-22 Resumed Wells Fargo Overweight
May-05-22 Upgrade Guggenheim Neutral → Buy
Mar-15-22 Initiated Evercore ISI Outperform
Dec-10-21 Upgrade SVB Leerink Mkt Perform → Outperform
Nov-17-21 Resumed Guggenheim Neutral
Oct-07-21 Initiated Jefferies Hold
Mar-31-21 Initiated Credit Suisse Outperform
Feb-25-21 Downgrade SVB Leerink Outperform → Mkt Perform
Feb-08-21 Resumed H.C. Wainwright Buy
Jan-25-21 Downgrade Citigroup Buy → Neutral
Sep-29-20 Resumed JP Morgan Neutral
Aug-06-20 Initiated SVB Leerink Outperform
Jan-10-20 Initiated Wolfe Research Outperform
Dec-09-19 Initiated JP Morgan Neutral
Nov-25-19 Initiated H.C. Wainwright Buy
Nov-20-19 Initiated Guggenheim Buy
Sep-30-19 Upgrade Raymond James Outperform → Strong Buy
Aug-30-19 Initiated Stifel Buy
Jul-18-19 Initiated Deutsche Bank Buy
May-11-18 Upgrade Barclays Underweight → Equal Weight
Mar-19-18 Initiated Raymond James Outperform
View All

Zymeworks Inc. Stock (ZYME) Latest News

pulisher
Aug 19, 2025

Implied Analyst Target Price of $70.96 for iShares Morningstar Small-Cap ETF (ISCB) Suggests 16% Gain Potential. - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Zymeworks to Engage in Key Investor Conferences - TipRanks

Aug 19, 2025
pulisher
Aug 19, 2025

Zymeworks to Participate in Upcoming Investor Conferences. - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Zymeworks' Strategic Momentum in 2025: A High-Conviction Biotech Play in the ADC and Bispecific Antibody Space - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Zymeworks Inc. to Participate in Multiple Upcoming Investor Conferences in September 2025 - Quiver Quantitative

Aug 19, 2025
pulisher
Aug 19, 2025

Zymeworks to Present at Several Upcoming Investor Conferences - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire

Aug 19, 2025
pulisher
Aug 19, 2025

Clinical-Stage Biotech Zymeworks Lines Up 4 Major Wall Street Healthcare Conference Presentations in September - Stock Titan

Aug 19, 2025
pulisher
Aug 19, 2025

RSI Crosses Above 30 for Zymeworks Inc. — Reversal in SightPortfolio Value Report & Weekly Watchlist of Top Performers - 선데이타임즈

Aug 19, 2025
pulisher
Aug 18, 2025

Short Interest Drops in Zymeworks Inc. After RallyMarket Growth Review & Fast Moving Market Watchlists - newsimpact.co.kr

Aug 18, 2025
pulisher
Aug 17, 2025

Is Zymeworks Inc. stock forming a triangle patternJuly 2025 Action & AI Forecast Swing Trade Picks - sundaytimes.kr

Aug 17, 2025
pulisher
Aug 16, 2025

What is the cash position of Zymeworks Inc.2025 Winners & Losers & Weekly Momentum Stock Picks - mustnews.co.kr

Aug 16, 2025
pulisher
Aug 16, 2025

Zymeworks Inc. Revenue Forecasts Upgraded by 44%: Analysts See Substantial Growth Ahead - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

Growth Investors: Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 44% - Yahoo Finance

Aug 16, 2025
pulisher
Aug 16, 2025

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - Caledon Enterprise

Aug 16, 2025
pulisher
Aug 14, 2025

Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

Will Breakout in Zymeworks Inc. Sustain Through Next WeekJuly 2025 Drop Watch & Free Technical Pattern Based Buy Signals - beatles.ru

Aug 14, 2025
pulisher
Aug 14, 2025

Screener Results Flag Zymeworks Inc. as OversoldTrade Risk Assessment & Free Reliable Trade Execution Plans - thegnnews.com

Aug 14, 2025
pulisher
Aug 14, 2025

Short Term Charts Align With Long Term Uptrend in Zymeworks Inc.July 2025 Review & Long-Term Capital Growth Strategies - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 14, 2025

Zymeworks Inc. Added to Custom Quant Screener Today2025 Buyback Activity & Free Fast Entry Momentum Trade Alerts - thegnnews.com

Aug 14, 2025
pulisher
Aug 14, 2025

Zymeworks (ZYME) Is Up 12.3% After Board Shakeup, Insider Investment, and Return to Profitability – Has The Bull Case Changed? - simplywall.st

Aug 14, 2025
pulisher
Aug 13, 2025

Zymeworks (NASDAQ:ZYME) Issues Earnings Results - MarketBeat

Aug 13, 2025
pulisher
Aug 12, 2025

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Zymeworks Inc. (NASDAQ:ZYME) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 12, 2025
pulisher
Aug 12, 2025

Zymeworks Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - 富途牛牛

Aug 12, 2025
pulisher
Aug 11, 2025

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - Ariva

Aug 11, 2025
pulisher
Aug 11, 2025

Zymeworks Strengthens Leadership with New Board Appointments - TipRanks

Aug 11, 2025
pulisher
Aug 11, 2025

Zymeworks Expands Board with Financial Veterans Greg Ciongoli and Robert E. Landry - The Indian Awaaz

Aug 11, 2025
pulisher
Aug 11, 2025

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry | ZYME Stock News - GuruFocus

Aug 11, 2025
pulisher
Aug 11, 2025

Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors - Quiver Quantitative

Aug 11, 2025
pulisher
Aug 11, 2025

Zymeworks appoints two new directors to strengthen board By Investing.com - Investing.com Canada

Aug 11, 2025
pulisher
Aug 11, 2025

Zymeworks appoints two new directors to strengthen board - Investing.com India

Aug 11, 2025
pulisher
Aug 11, 2025

Zymeworks Strengthens Board with Healthcare Veterans as Key Trial Results Near - Stock Titan

Aug 11, 2025
pulisher
Aug 11, 2025

Will breakout in Zymeworks Inc. lead to full recoveryFree Breakout Entry Signal Confirmation Tool - Newser

Aug 11, 2025
pulisher
Aug 10, 2025

Has Zymeworks Inc. formed a bullish divergenceLow Risk Stock Selection Strategy Guide - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Zymeworks Inc. stock trendline breakdownFree Scalable Portfolio Growth Suggestions - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Zymeworks Inc. stock outlook for YEARWealth Accumulation Outlook for Safe Investors - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - simplywall.st

Aug 10, 2025
pulisher
Aug 10, 2025

Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance

Aug 10, 2025
pulisher
Aug 10, 2025

Is Zymeworks Inc. forming a breakout patternDouble Capital Strategy Picks - thegnnews.com

Aug 10, 2025
pulisher
Aug 10, 2025

Can Zymeworks Inc. hit a new high this monthFree Proven Entry Plan With Low Risk Trade - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Aug 10, 2025
pulisher
Aug 10, 2025

Applying sector rotation models to Zymeworks Inc.Technical Reversal Setup with Risk Limits - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

What does recent volatility data suggest for Zymeworks Inc.Stock Price Prediction Using AI Tools - Newser

Aug 10, 2025
pulisher
Aug 09, 2025

Why Zymeworks Inc. stock attracts strong analyst attentionFree High Yield Stocks With Buy Confirmation - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Is Zymeworks Inc. affected by consumer sentimentStock Picks with 300% Gain - sisaissue.com

Aug 09, 2025
pulisher
Aug 09, 2025

Zymeworks Q2 2025 Earnings Call: Capitalizing on Platform-Driven Innovation and Strategic Execution - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Zurcher Kantonalbank Zurich Cantonalbank Purchases 4,920 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World

Aug 09, 2025
pulisher
Aug 09, 2025

Zymeworks (NASDAQ:ZYME) Lowered to “Hold” Rating by Wall Street Zen - Defense World

Aug 09, 2025
pulisher
Aug 09, 2025

Zymeworks Reports Strong Q2 2025 Financial Performance - The Globe and Mail

Aug 09, 2025
pulisher
Aug 08, 2025

Zymeworks Reports Q2 Results and FDA Clearance - The Globe and Mail

Aug 08, 2025

Zymeworks Inc. Stock (ZYME) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Zymeworks Inc. Stock (ZYME) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
EcoR1 Capital, LLC
Director
May 19 '25
Buy
11.78
5,919
69,738
17,883,908
EcoR1 Capital, LLC
Director
Apr 16 '25
Buy
11.16
73,953
825,589
17,773,727
EcoR1 Capital, LLC
Director
Apr 17 '25
Buy
11.52
54,760
630,819
17,828,487
EcoR1 Capital, LLC
Director
Apr 04 '25
Buy
11.17
196,438
2,193,800
17,699,774
EcoR1 Capital, LLC
Director
Apr 03 '25
Buy
11.84
120,770
1,430,170
17,503,336
EcoR1 Capital, LLC
Director
Apr 02 '25
Buy
11.85
74,360
881,017
17,382,566
EcoR1 Capital, LLC
Director
Apr 01 '25
Buy
11.60
48,658
564,647
17,308,206
EcoR1 Capital, LLC
Director
Mar 31 '25
Buy
11.75
4,397
51,658
17,259,548
EcoR1 Capital, LLC
Director
Mar 25 '25
Buy
12.91
53,501
690,452
17,211,303
EcoR1 Capital, LLC
Director
Mar 26 '25
Buy
12.24
43,848
536,857
17,255,151
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):